Sentences with phrase «for preclinical stage»

Work experiences listed on sample resumes of Planning Managers include skills like providing recommendations regarding market potential for new targets including, but not limited to, indication prioritization and fast - to - market strategies, and providing commercial analysis in order to gain partnering opportunities for preclinical stage compounds.

Not exact matches

Gain Therapeutics (www.gaintherapeutics.com) is a preclinical stage biotech company developing a class of next generation pharmacological chaperones for the treatment of devastating rare diseases using the SEE - Tx technology.

MIN - 102, Minoryx's candidate for X-ALD, is in the preclinical stage.

For example, Matt Krause, director of human resources at CV Therapeutics, says, «Our research programs include multiple, cutting - edge cardiovascular product candidates in various stages of clinical trials and preclinical programs, all of which rely heavily on the contributions from our many B.S. - and M.S. - level scientists.»

According to a recent study of Framingham Study participants, nearly 60 percent of people have prevalent preclinical heart failure (HF) stages A and B. Heart failure occurs when the heart muscle is weakened and can not pump enough blood to meet the body's needs for blood and oxygen.

Of note, nearly 38 percent of people between ages 65 to 75 years and 43 percent of those older than age 75 years had evidence of preclinical HF stage B. Additionally, 32 percent of people less than 55 years of ages were classified as stage A HF,» explained corresponding author Vanessa Xanthakis, PhD, assistant professor of medicine and biostatistics at BUSM and an Investigator for the Framingham Heart Study.

Katherine W. Klinger, PhD, Senior Vice President for Genetics and Genomics at the Genzyme Corporation, and Assistant Clinical Professor in the Department of Pediatrics at the University of Connecticut School of Medicine suggested that for an orphan disease it may be necessary to use multiple animal models in the preclinical research stage, because one animal model may not fully recapitulate the human disease.

Both recent experience with immunotherapy for clearance of Aβ in AD, and their own (and Prothena's) experience with AS - clearing immunotherapies in animal models, indicate that in order to be effective as disease - modifying agents when administered alone, therapies that remove proteinaceous aggregates from the brain must be initiated in the early clinical or even preclinical stages of the disease, before the burden of other forms of aging damage becomes entrenched.

It is estimated that 1 dog in 10 suffers from some type of heart disease.1 The statistics for valvular heart disease are even more sobering, ranging from 10 percent of young dogs to as high as 35 percent of dogs ages 13 years and older.2 Although there are a number of treatment options for dogs with CHF caused by MMVD, there had been no consensus on what treatments could be beneficial in the preclinical stage of heart disease.3